(Health Korea News / Changyong Lee) ‘Pharmaceutical 24 Hours’ is a corner that shows brief news related to pharmaceutical and biotechnology at a glance that is easy to miss. It may seem like trivial news, but it could be valuable information to someone, so we summarize the facts and present them in an easy-to-understand manner.
◆ Korea Pharmaceutical Import and Export Association holds the 1st Imported Drug Subcommittee
The Korea Pharmaceutical Import and Export Association held the first Imported Drug Subcommittee (Committee) of 2025 in the conference room of the Korea Pharmaceutical Import and Export Association on the 9th.
Kim Woo-tae, CEO of Guju Pharmaceutical, served as the chairman, and Lee Seung-young, CEO of Daehan Pharmaceutical Industry Co., Ltd., served as vice chairman. The committee consists of 12 members, including executives from member companies, and was formed to reflect the expertise of each product, including chemical synthetic drugs, biopharmaceuticals, and radiopharmaceuticals.
The Imported Pharmaceuticals Subcommittee listens to industry difficulties, focuses on establishing quality control and distribution order for pharmaceuticals, etc., and improves policies and systems related to imported pharmaceuticals, identifies areas for improvement, and makes policy recommendations to relevant government ministries to develop the industry. We are working hard on
◆ LG Chem plans to expand its aesthetic business in Thailand
LG Chem is strengthening its business competitiveness in the Thai aesthetic market.
LG Chem announced on the 10th that it has begun sales of its PN (polynucleotide) ingredient skin booster ‘HP VITARAN (export name: HP Cell VITARAN i)’ in Thailand. Based on the Thai subsidiary’s direct sales network, the aesthetic product line has been expanded following the cosmetic filler ‘YVOIRE’, which was first introduced in Thailand in 2021. By maximizing the synergy between the two products, it is expected that further momentum will be gained in targeting the Thai market, a representative high-growth country in the medical beauty industry.
‘Vitaran’ is a skin booster medical device introduced last year by ‘BR Pharm’, a regenerative medicine technology research and manufacturing company. It is characterized by an injectable formulation and high-quality raw materials.
Unlike skin booster products approved as cosmetics, skin booster medical devices can be injected into the skin, so direct skin improvement effects can be expected. BR Farm Trout Farm, a basic raw material production base, has secured reliability in raw material quality control by obtaining certification as a suitable facility (no radioactivity and heavy metals detected) as a result of a seafood safety investigation by the Jeonnam Marine Fisheries Research Institute.
◆ Aprogen completes acquisition of management stake in Geolit Energy… Begins full-fledged entry into Parkinson’s disease treatment
Aprogen has laid the foundation for entry into the degenerative brain disease treatment market, which the company has ambitiously declared a challenge for.
Aprogen, a domestic biosimilar company, announced on the 10th that it completed the acquisition of the management stake in Geolit Energy owned by N2Tech. It acquired 27,349,049 shares of Geolit Energy for 41 billion won, securing a 17.22% stake in the company.
On the 5th of last month, Geolit Energy signed a contract to acquire three patents for Parkinson’s disease treatment developed by Professor Jeong Jong-kyung of Seoul National University for 5.4 billion won in order to enter the Parkinson’s disease treatment market. Professor Jong-Kyung Jeong, director of Seoul National University’s Genetic Engineering Research Institute, is one of the world’s top scientists in the field of Parkinson’s disease and has worked to identify the cause of Parkinson’s disease and develop treatments for the past 25 years. There are more than 110 research papers published as lead or corresponding author in the world’s top academic journals.
Professor Jeong is scheduled to take office as the CEO and President of Geolit Energy’s brain disease treatment business division as soon as the review for permission to hold concurrent positions currently underway at Seoul National University is completed.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
